Sarcomatoid Carcinoma, a Variant Histology of the Bladder: Case Series and Literature Review

Year 2019, Volume: 14 Issue: 3, 182 - 188, 01.10.2019

Yavuz Onur Danacıoğlu , Rabia Burçin Girgin Ferhat Keser , Asıf Yıldırım

https://doi.org/10.33719/yud.524193

Abstract

Objective: Sarcomatoid urothelial carcinoma has an aggressive nature; a worse prognosis, a more advanced stage and a greater risk of metastasis than other types of urothelial cancers. In this study, the clinical and histopathological results of 10 patients with sarcomatoid urothelial carcinoma of the bladder will be presented and the current literature will be reviewed.

Material and Methods: The study included 10 patients histopathologically diagnosed as sarcomatoid carcinoma between November 2012 and December 2018.  Demographic characteristics and pathology results were evaluated retrospectively. Patients were evaluated with detailed history, physical examination, routine biochemical and hematological examination, urinary ultrasonography, abdominopelvic tomography, chest radiography and cystoscopy before surgery.

Results: The mean age and mean followup period of the patients were 70.2 (51-81) years and 9.2 (2-18) months respectively. The mean symptom of the patients was macroscopic hematuria. Six (60%) patients underwent radical cystectomy. One patient received neoadjuvant chemotherapy. One (16.6%) patient had a stage of pT2b tumor, three (50%) patients had a stage of pT3 tumor and two (33.3%) patients had a stage of pT4 tumor after radical cystectomy. Three (50%) patients were found to have N1 disease and three (50%) patients had coexisting carcinoma in situ (CIS). Metastasis for lymph node involvement was present in three (50%) of the patients. Six (60%) patients have died due to disease, four (40%) patients are still continued to follow up.

Conclusion: Sarcomatoid carcinoma of the bladder is usually an aggressive tumor and patients are referred with advanced stages. Despite radical surgery, these patients should be followed up closely as early recurrence and progression can be seen.

Keywords

Bladder cancer , sarcomatoid carcinoma , variant histology

Mesanenin Sarkomatoid Karsinom Varyant Histolojisi: Olgu Serisi ve Lliteratür Değerlendirmesi

Abstract

Amaç: Agresif seyirli olan sarkomatoid ürotelyal karsinomlar,
diğer ürotelyal kanser tiplerine göre daha kötü prognoza, daha ileri evreye ve
daha fazla oranda metastaz riskine sahiptirler. Bu çalışmada mesanenin sarkomatoid
ürotelyal karsinomu tanısı alan 10 hastanın klinik ve histopatolojik sonuçları
literatür eşliğinde sunulacaktır.

Materyal
ve Metod: Çalışmaya Kasım 2012 ve Aralık 2018 tarihleri arasında
histopatolojik olarak sarkomatoid karsinom tanısı alan 10 hasta dahil edildi.
Hastaların demografik özellikleri ve patoloji sonuçları retrospektif olarak
değerlendirildi. Hastalar
ameliyat öncesi ayrıntılı öykü, fiziksel inceleme, rutin biyokimyasal ve
hematolojik tetkikler, üriner ultrasonografi, abdominopelvik tomografi, akciğer
grafileri ve sistoskopi ile değerlendirildiler.

Bulgular: Hastaların ortalama yaşı ve ortalama
takip süreleri sırası ile 70,2 (51-81) yıl ve 9,2
(2-18) ay olarak saptandı. Hastaların başvuru
şikayetlerinin makroskopik hematüri olduğu gözlendi. Altı (%50) hastaya radikal
sistektomi ameliyatı uygulandı. Bir hasta neoadjuvan kemoterapi aldı. Radikal
sistektomi sonrasında 1
(%16,6) hastada evre pT2b tümör, 3 (%50) hastada evre pT3 tümör ve 2 (%33,3)
hastada evre pT4 tümörün olduğu görüldü. Üç (%50) hastanın N1 olduğu görüldü ve
üç (%50) hastada eşlik eden CIS varlığı saptandı. Lenf nodu tutulumu açısından 3 (%50) hastada metastaz mevcuttu. Yapılan takiplerde 6 (%60) hastada hastalığa bağlı ölüm görülürken, 4 (%40) hasta halen
takip edilmektedir.

Sonuç: Mesanenin sarkomatoid karsinomları
genelde agresif seyretmekte ve hastalar ileri evre tümörle tarafımıza
başvurmaktadırlar. Radikal cerrahi tedaviye karşın bu tür tümörlerin erken nüks
ve progresyon göstereceği göz önünde bulundurularak bu hastaların yakın takip
edilmeleri gerekmektedir.

 

 

 

Keywords

Mesane tümörü , sarkomatoid karsinom , Varyant histoloji

References

• 1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: IARC. 2013.
• 2. Reisz PA, Laviana AA, Chang SS. Management of High-grade T1 Urothelial Carcinoma. Curr Urol Rep 2018;19:103.
• 3. Müller-Hermelink HK, Engel P, Kuo T, et al. Pathology & genetics, tumours of the lung, pleura, thymus and heart. World Health Organization Classification of Tumors Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, Eds IARC Press, Lyon. 2004:146-47.
• 4. Klaile Y, Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe L-M. Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? Transl Androl Urol 2016;5:692.
• 5. Wang J, Wang FW, LaGrange CA, Hemstreet III GP, Kessinger A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma. 2010;2010.
• 6. Stamatiou K, Galariotis N, Michailidis I, Petrakopoulou N, Moustou H, Zizi-Sermpetzoglou A. Sarcomatoid carcinoma of the urinary bladder: a clinicopathological study of 4 cases and a review of the literature. Korean J Urol 2010;51:724-28.
• 7. Rabson SM. Atypical Carcinoma of the Urinary Bladder Simulating Myosarcoma: Report of Two Cases and Review of the Literature1. J Urol 1935;34:638-69.
• 8. Cheng L, Zhang S, Alexander R, , et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol 2011;35:e34-e46.
• 9. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B:
• 10. Baseskioglu B, Duman BB, Kara IO, Can C, Yildirim M, Acikalin M. Early detection and gemcitabine/cisplatin combination positively effect survival in sarcomatoid carcinoma of the urinary bladder. Asian Pac J Cancer Prev 2012;13:5729-33.
• 11. Erdemir F, Uluocak N, Tunç M, Öcan F, Gökçe Ö, Kılıçaslan I. Mesanenin sarkomatoid kanseri. Turk J Urol 2006;32:462-66.
• 12. Moschini M, D'andrea D, Korn S, Irmak Y, Soria F, Compérat E, et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 2017;14:651.
• 13. Mukhopadhyay S, Shrimpton AE, Jones LA, Nsouli IS, Abraham Jr NZ. Carcinosarcoma of the urinary bladder following cyclophosphamide therapy: evidence for monoclonal origin and chromosome 9p allelic loss. Arch Pathol Lab Med 2004;128:e8-e11.
• 14. Young RH, Eble JN. Unusual forms of carcinoma of the urinary bladder. Human pathology 1991;22:948-65.
• 15. Gronau S, Menz CK, Melzner I, Hautmann R, Möller P, Barth TF. Immunohistomorphologic and molecular cytogenetic analysis of a carcinosarcoma of the urinary bladder. Virchows Arch 2002;440:436-40.
• 16. Sanchez JEH, Figueira YR, Gonzalez RT, Lopez RM, Tejeda LMG. Sarcomatoid carcinoma of the urinary bladder: a case report and review of the literature. J Med Cases 2014;5:116-19.
• 17. Choi H-R, Sturgis EM, Rosenthal DI, Luna MA, Batsakis JG, El-Naggar AK. Sarcomatoid carcinoma of the head and neck: molecular evidence for evolution and progression from conventional squamous cell carcinomas. Am J Surg Pathol 2003;27:1216-20.
• 18. Lewis Jr JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder—p63, MOC-31, and TTF-1. Modern Pathology 2005;18:1471.
• 19. Lekas A, Parasi A, Papathomas TG, et al. Pseudosarcomatous myofibroblastic lesion of the urinary bladder: A rare entity posing a diagnostic challenge and therapeutic dilemma. Diagnostic pathology 2008;3:11.
• 20. Malla M, Wang JF, Trepeta R, Feng A, Wang J. Sarcomatoid carcinoma of the urinary bladder. Clin Genitourin Cancer 2016;14:366-72.
• 21. Lopez-Beltran A, Pacelli A, Rothenberg H, et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 1998;159:1497-503.